|
1
|
Peach MJ: Renin-angiotensin system:
biochemistry and mechanisms of action. Physiol Rev. 57:313–370.
1977.PubMed/NCBI
|
|
2
|
Deshayes F and Nahmias C: Angiotensin
receptors: a new role in cancer? Trends Endocrinol Metab.
16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tamarat R, Silvestre JS, Durie M and Levy
BI: Angiotensin II angiogenic effect in vivo involves vascular
endothelial growth factor- and inflammation-related pathways. Lab
Invest. 82:747–756. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pupilli C, Lasagni L, Romagnani P, Bellini
F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D and
Serio M: Angiotensin II stimulates the synthesis and secretion of
vascular permeability factor/vascular endothelial growth factor in
human mesangial cells. J Am Soc Nephrol. 10:245–255.
1999.PubMed/NCBI
|
|
5
|
Otani A, Takagi H, Oh H, Koyama S and
Honda Y: Angiotensin II induces expression of the Tie2 receptor
ligand, angiopoietin-2, in bovine retinal endothelial cells.
Diabetes. 50:867–875. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fujita M, Hayashi I, Yamashina S, Itoman M
and Majima M: Blockade of angiotensin AT1a receptor signaling
reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys
Res Commun. 294:441–447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suganuma T, Ino K, Shibata K, Kajiyama H,
Nagasaka T, Mizutani S and Kikkawa F: Functional expression of the
angiotensin II type 1 receptor in human ovarian carcinoma cells and
its blockade therapy resulting in suppression of tumor invasion,
angiogenesis, and peritoneal dissemination. Clin Cancer Res.
11:2686–2694. 2005. View Article : Google Scholar
|
|
8
|
Yasumatsu R, Nakashima T, Masuda M, Ito A,
Kuratomi Y, Nakagawa T and Komune S: Effects of the angiotensin-I
converting enzyme inhibitor perindopril on tumor growth and
angiogenesis in head and neck squamous cell carcinoma cells. J
Cancer Res Clin Oncol. 130:567–573. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neo JH, Malcontenti-Wilson C, Muralidharan
V and Christophi C: Effect of ACE inhibitors and angiotensin II
receptor antagonists in a mouse model of colorectal cancer liver
metastases. J Gastroenterol Hepatol. 22:577–584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ebert MP, Lendeckel U, Westphal S, Dierkes
J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P and
Röcken C: The angiotensin I-converting enzyme gene
insertion/deletion polymorphism is linked to early gastric cancer.
Cancer Epidemiol Biomarkers Prev. 14:2987–2389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Röcken C, Lendeckel U, Dierkes J, Westphal
S, Carl-McGrath S, Peters B, Krüger S, Malfertheiner P, Roessner A
and Ebert MP: The number of lymph node metastases in gastric cancer
correlates with the angiotensin I-converting enzyme gene
insertion/deletion polymorphism. Clin Cancer Res. 11:2526–2530.
2005.PubMed/NCBI
|
|
12
|
Röcken C, Röhl FW, Diebler E, Lendeckel U,
Pross M, Carl-McGrath S and Ebert MP: The angiotensin
II/angiotensin II receptor system correlates with nodal spread in
intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev.
16:1206–1212. 2007.PubMed/NCBI
|
|
13
|
Wasa J, Sugiura H, Kozawa E, Kohyama K,
Yamada K and Taguchi O: The tumor suppressive effect of angiotensin
II type 1 receptor antagonist in a murine osteosarcoma model.
Anticancer Res. 31:123–127. 2011.PubMed/NCBI
|
|
14
|
Santos RA, Simoes e Silva AC, Maric C,
Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV,
Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ,
Schultheiss HP, Speth R and Walther T: Angiotensin-(1–7) is an
endogenous ligand for the G protein-coupled receptor Mas. Proc Natl
Acad Sci USA. 100:8258–8263. 2003.
|
|
15
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y,
Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration
and invasion of A549 human lung adenocarcinoma cells through
inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol
Rep. 27:783–790. 2012.
|
|
16
|
Gallagher PE and Tallant EA: Inhibition of
human lung cancer cell growth by angiotensin-(1–7). Carcinogenesis.
25:2045–2052. 2004.
|
|
17
|
Feng Y, Ni L, Wan H, Fan L, Fei X, Ma Q,
Gao B, Xiang Y, Che J and Li Q: Overexpression of ACE2 produces
antitumor effects via inhibition of angiogenesis and tumor cell
invasion in vivo and in vitro. Oncol Rep. 26:1157–1164.
2011.PubMed/NCBI
|
|
18
|
Qian YR, Guo Y, Wan HY, Fan L, Feng Y, Ni
L, Xiang Y and Li QY: Angiotensin-converting enzyme 2 attenuates
the metastasis of non-small cell lung cancer through inhibition of
epithelial-mesenchymal transition. Oncol Rep. 29:2408–2414.
2013.PubMed/NCBI
|
|
19
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu W and Zhao S: Metabolic changes in
cancer: beyond the Warburg effect. Acta Biochim Biophys Sin
(Shanghai). 45:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cifuentes M, García MA, Arrabal PM,
Martínez F, Yañez MJ, Jara N, Weil B, Domínguez D, Medina RA and
Nualart F: Insulin regulates GLUT1-mediated glucose transport in
MG-63 human osteosarcoma cells. J Cell Physiol. 226:1425–1432.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Costelloe CM, Macapinlac HA, Madewell JE,
Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO,
Anderson PM, Bassett RL Jr, Harrell RK and Marom EM: 18F-FDG PET/CT
as an indicator of progression-free and overall survival in
osteosarcoma. J Nucl Med. 50:340–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Franzius C, Bielack S, Flege S, Sciuk J,
Jürgens H and Schober O: Prognostic significance of (18)F-FDG and
(99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J
Nucl Med. 43:1012–1017. 2002.PubMed/NCBI
|
|
24
|
Liu C, Lv XH, Li HX, Cao X, Zhang F, Wang
L, Yu M and Yang JK: Angiotensin-(1–7) suppresses oxidative stress
and improves glucose uptake via Mas receptor in adipocytes. Acta
Diabetol. 49:291–299. 2012.
|
|
25
|
Giani JF, Mayer MA, Muñoz MC, Silberman
EA, Höcht C, Taira CA, Gironacci MM, Turyn D and Dominici FP:
Chronic infusion of angiotensin-(1–7) improves insulin resistance
and hypertension induced by a high-fructose diet in rats. Am J
Physiol Endocrinol Metab. 296:E262–E271. 2009.
|
|
26
|
Lever AF, Hole DJ, Gillis CR, McCallum IR,
McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and
Robertson JW: Do inhibitors of angiotensin-I-converting enzyme
protect against risk of cancer? Lancet. 352:179–184. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Friis S, Sørensen HT, Mellemkjaer L,
McLaughlin JK, Nielsen GL, Blot WJ and Olsen JH:
Angiotensin-converting enzyme inhibitors and the risk of cancer: a
population-based cohort study in Denmark. Cancer. 92:2462–2470.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young D, Waitches G, Birchmeier C, Fasano
O and Wigler M: Isolation and characterization of a new cellular
oncogene encoding a protein with multiple potential transmembrane
domains. Cell. 45:711–719. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alenina N, Xu P, Rentzsch B, Patkin EL and
Bader M: Genetically altered animal models for Mas and
angiotensin-(1–7). Exp Physiol. 93:528–537. 2008.PubMed/NCBI
|
|
30
|
Hönicke A-S, Ender SA and Radons J:
Combined administration of EGCG and IL-1 receptor antagonist
efficiently downregulates IL-1-induced tumorigenic factors in U-2
OS human osteosarcoma cells. Int J Oncol. 41:753–758. 2012.
|
|
31
|
Chilukotia RK, Mostertz J, Bukowska A,
Aderkast C, Felix SB, Busch M, Völker U, Goette A, Wolke C, Homuth
G and Lendeckel U: Effects of irbesartan on gene expression
revealed by transcriptome analysis of left atrial tissue in a
porcine model of acute rapid pacing in vivo. Int J Cardiol.
168:2100–2108. 2013. View Article : Google Scholar : PubMed/NCBI
|
